What is Enzo Biochem Debt-to-Equity?
Enzo Biochem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $0.90 Mil. Enzo Biochem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $2.36 Mil. Enzo Biochem's Total Stockholders Equity for the quarter that ended in Oct. 2024 was $47.66 Mil.
Enzo Biochem's debt to equity for the quarter that ended in Oct. 2024 was 0.07.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Enzo Biochem's Debt-to-Equity or its related term are showing as below:
ENZ'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.1 Max: 1.16
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of Enzo Biochem was 1.16. The lowest was 0.00. And the median was 0.10.
Enzo Biochem Debt-to-Equity Historical Data
The historical data trend for Enzo Biochem's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzo Biochem Debt-to-Equity Chart
|
Enzo Biochem Annual Data
|
|
Trend |
Jul15 |
Jul16 |
Jul17 |
Jul18 |
Jul19 |
Jul20 |
Jul21 |
Jul22 |
Jul23 |
Jul24 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.56 |
0.33 |
0.17 |
0.09 |
0.06 |
|
Enzo Biochem Quarterly Data
|
|
Jan20 |
Apr20 |
Jul20 |
Oct20 |
Jan21 |
Apr21 |
Jul21 |
Oct21 |
Jan22 |
Apr22 |
Jul22 |
Oct22 |
Jan23 |
Apr23 |
Jul23 |
Oct23 |
Jan24 |
Apr24 |
Jul24 |
Oct24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.10 |
0.10 |
0.11 |
0.06 |
0.07 |
Competitive Comparison of Enzo Biochem's Debt-to-Equity
For the Diagnostics & Research subindustry, Enzo Biochem's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzo Biochem's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Enzo Biochem's Debt-to-Equity falls into.
Enzo Biochem Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Enzo Biochem's Debt to Equity Ratio for the fiscal year that ended in Jul. 2024 is calculated as
Enzo Biochem's Debt to Equity Ratio for the quarter that ended in Oct. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzo Biochem Business Description
Traded in Other Exchanges
Address
21 Executive Boulevard, Farmingdale, NY, USA, 11735
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.
Executives
| Steven J Pully |
director |
9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042 |
| James G. Wolf |
10 percent owner |
105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455 |
| Hamid Erfanian |
officer: Chief Executive Officer |
527 MADISON AVENUE, NEW YORK NY 10022 |
| Patricia Eckert |
officer: Interim CFO |
C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735 |
| Kara Cannon |
officer: Chief Operating Officer |
527 MADISON AVE, NEW YORK NY 10022 |
| Bradley Louis Radoff |
director |
2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098 |
| David Bench |
officer: CHIEF FINANCIAL OFFICER |
ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
| Harbert Discovery Fund, Lp |
10 percent owner |
HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
| Ian B. Walters |
director |
ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
| Mary Tagliaferri |
director |
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
| Clemens Peter J Iv |
10 percent owner |
2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069 |
| Rebecca J. Fischer |
director |
ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
| Fabian Blank |
10 percent owner, other: See Remarks |
ROEMERSTRASSE 6, BAD BERTRICH 2M 56864 |
| Harbert Management Corp |
10 percent owner |
2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
| Harbert Discovery Co-investment Fund I Gp, Llc |
10 percent owner |
2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENZ has been successfully added to your